Last reviewed · How we verify
SR-A + Epratuzumab
SR-A combined with epratuzumab targets CD19-positive B cells to deplete autoreactive B cells in systemic lupus erythematosus.
SR-A combined with epratuzumab targets CD19-positive B cells to deplete autoreactive B cells in systemic lupus erythematosus. Used for Systemic lupus erythematosus (SLE).
At a glance
| Generic name | SR-A + Epratuzumab |
|---|---|
| Also known as | Epratuzumab |
| Sponsor | Charite University, Berlin, Germany |
| Drug class | BTK inhibitor + monoclonal antibody combination |
| Target | BTK and CD19 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
SR-A is a selective Bruton's tyrosine kinase (BTK) inhibitor that suppresses B cell activation and survival, while epratuzumab is a monoclonal antibody targeting CD19 on B cell surfaces. Together, they work synergistically to reduce pathogenic B cell populations and autoimmune responses in lupus patients.
Approved indications
- Systemic lupus erythematosus (SLE)
Common side effects
- Infection
- Cytopenias
- Infusion reactions
Key clinical trials
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (PHASE3)
- International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |